Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8IU60

UPID:
DCP2_HUMAN

ALTERNATIVE NAMES:
Nucleoside diphosphate-linked moiety X motif 20; mRNA-decapping enzyme 2

ALTERNATIVE UPACC:
Q8IU60; C9J778; Q6P2D4; Q7Z5W5; Q8NBG5

BACKGROUND:
Nucleoside diphosphate-linked moiety X motif 20, known as mRNA-decapping enzyme 2, plays a vital role in mRNA metabolism. By cleaving the cap structure on mRNAs, it facilitates mRNA degradation, impacting gene expression. Its higher activity towards mRNAs without a poly(A) tail and resistance to decapping by N(6)-methyladenosine methylation are notable.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of mRNA-decapping enzyme 2 in mRNA turnover provides a foundation for developing novel therapeutic approaches. As a regulator of gene expression, targeting this enzyme could lead to innovative treatments for conditions characterized by abnormal mRNA stability and gene expression patterns.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.